Cargando…
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients
The deletion of exons 9 to 12 of BRCA1 (9–12 del BRCA1) is considered a founder mutation in the Mexican population. We evaluate the usefulness of the target detection of 9–12 del BRCA1 as the first molecular diagnostic strategy in patients with Hereditary Breast and Ovarian Cancer (HBOC). We perform...
Autores principales: | Fragoso-Ontiveros, Veronica, Velázquez-Aragón, Jose Antonio, Nuñez-Martínez, Paulina Maria, de la Luz Mejía-Aguayo, Maria, Vidal-Millán, Silvia, Pedroza-Torres, Abraham, Sánchez-Contreras, Yuliana, Ramírez-Otero, Miguel Angel, Muñiz-Mendoza, Rodolfo, Domínguez-Ortíz, Julieta, Wegman-Ostrosky, Talia, Bargalló-Rocha, Juan Enrique, Gallardo-Rincón, Dolores, Reynoso-Noveron, Nancy, Arriaga-Canon, Cristian, Meneses-García, Abelardo, Herrera-Montalvo, Luis Alonso, Alvarez-Gomez, Rosa Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756553/ https://www.ncbi.nlm.nih.gov/pubmed/31545835 http://dx.doi.org/10.1371/journal.pone.0222709 |
Ejemplares similares
-
A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population
por: Padua-Bracho, Alejandra, et al.
Publicado: (2022) -
Cancer Prevention Behaviors in Workers of a Referral Cancer Center in
Mexico City: A Pilot Study on Early Detection Awareness for
Cancer
por: Reynoso-Noverón, Nancy, et al.
Publicado: (2022) -
MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities
por: Pedroza-Torres, Abraham, et al.
Publicado: (2019) -
Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma
por: Perdomo-Pantoja, Alexander, et al.
Publicado: (2018) -
Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular
por: Reynoso-Noverón, Nancy, et al.
Publicado: (2017)